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Abstract
Background: Diabetic nephropathy (DN) affects about 30% of patients with type 1 diabetes (T1D) and contributes to serious
morbidity and mortality. So far only the 3q21–q25 region has repeatedly been indicated as a susceptibility region for DN.
The aim of this study was to search for new DN susceptibility loci in Finnish, Danish and French T1D families.
Methods and Results: We performed a genome-wide linkage study using 384 microsatellite markers. A total of 175 T1D
families were studied, of which 94 originated from Finland, 46 from Denmark and 35 from France. The whole sample set
consisted of 556 individuals including 42 sib-pairs concordant and 84 sib-pairs discordant for DN. Two-point and multi-point
non-parametric linkage analyses were performed using the Analyze package and the MERLIN software. A novel DN locus on
22q11 was identified in the joint analysis of the Finnish, Danish and French families by genome-wide multipoint non-
parametric linkage analysis using the Kong and Cox linear model (NPLpairs LOD score 3.58). Nominal or suggestive evidence
of linkage to this locus was also detected when the three populations were analyzed separately. Suggestive evidence of
linkage was found to six additional loci in the Finnish and French sample sets.
Conclusions: This study identified a novel DN locus at chromosome 22q11 with significant evidence of linkage to DN. Our
results suggest that this locus may be of importance in European populations. In addition, this study supports previously
indicated DN loci on 3q21–q25 and 19q13.
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Introduction
Diabetic nephropathy (DN) is a major complication in patients
with type 1 diabetes (T1D) and contributes to serious morbidity
and mortality. It affects about one-third of the patients [1,2] and is
characterized by high blood pressure, proteinuria, a progressive
decline in renal function and an increased risk of cardiovascular
disease.
The incidence of DN reaches its peak after 20 years of diabetes
[1,2]. The observed incidence pattern and familial clustering [3–6]
suggest an important role for genetic factors in the development
and progression of DN. Although the majority of sib-pairs with
T1D are discordant for DN, its presence in one sibling doubles the
risk (l=2.1) for the other sibling with diabetes [5,6].
The chromosome region 3q21–q25 has been linked to DN in
patients with T1D in several genetic studies [7–10]. Apart from a
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24053genetic variant recently identified at 3q22 [11] no other genetic
variants that convincingly predispose to DN in patients with T1D
have been identified [12,13]. Findings from numerous case-control
candidate gene association studies have to a large extent been
contradictory and the studies have often been performed in a small
number of subjects and with a relatively limited set of markers
analyzed. Results from a recent genome-wide association study
(GWAS) [14] suggest novel pathways in the pathogenesis of DN.
In general, a common trend in GWAS data has been that the best
signals are detected in regions not previously studied using the
candidate gene approach. This suggests that different study designs
and approaches are needed to detect susceptibility loci for complex
diseases such as DN.
The aim of this study was to search for susceptibility loci for DN
in Finnish, Danish and French T1D families using a genome-wide
linkage strategy. We found a new susceptibility locus and were able
to replicate two previously identified loci.
Methods
Ethics Statement
All participants provided written, informed consent. Approvals
to conduct the research were obtained from the Helsinki
University Central Hospital Ethics Committee, Finland, the
Ethical Committee of Copenhagen, Denmark, and the Angers
University Ethics Committee, France. The study was in accor-
dance with the principle of the Helsinki Declaration.
Families
Altogether 175 Finnish, Danish and French families with T1D
were studied. The families were mainly nuclear families including
one or both parents and siblings concordant or discordant for DN
or solely sib-pairs concordant or discordant for DN. In addition,
sib-pairs with T1D and normal renal status were included. Patients
with DN were identified among those with age of onset of T1D at
35 years or less and who had had T1D for at least 10 years. The
distribution of siblings per family and the number of parents and
other relatives studied are presented in Table 1.
The Finnish families were recruited by the Finnish Diabetic
Nephropathy (FinnDiane) Study Group [15]. All adult T1D
patients, treated at the FinnDiane centers around the country,
were invited to participate in the study. The patients were asked
about their family history and a special effort was made to recruit
families with more than one patient with T1D. If the parents were
not alive, non-diabetic siblings were invited to participate in the
study. A total of 94 Finnish families were recruited 93 of which
had at least two siblings with T1D (Table 1).
In Denmark, a nationwide survey of the Danish Registry of
Diagnosis was used to identify patients diagnosed with T1D and
DN. After verification of patient records, a letter of invitation was
sent to all patients with a diabetic sibling. A total of 46 families
with at least two siblings with T1D were included in the study
(Table 1).
The French and Belgian families (from now on indicated as
French families) were collected on the occasion of the Genesis
(Genetic Nephropathy Sib pair Study) France-Belgium study [16].
Family information was obtained from medical examination and/
or structured questionnaire. A total of 35 families with at least two
siblings with T1D were included in the study (Table 1).
Diagnoses
The diagnosis of T1D was based on age at onset less than 35
years and permanent insulin treatment initiated within one year of
the diagnosis. Normal renal status, i.e. normoalbuminuria (DN2),
was defined as an albumin excretion rate (AER) ,20 mg/min or
,30 mg/24 h in two out of three consecutive overnight or 24-
hour urine collections. Incipient nephropathy (microalbuminuria)
was defined as an AER 20–200 mg/min or 30–300 mg/24 h and
overt nephropathy (proteinuria, DN+) as an AER .200 mg/min
or .300 mg/24 h. The patients on dialysis or with a kidney
transplant due to diabetic nephropathy were also considered to
have nephropathy (DN+). Retinopathy was defined as the
presence or absence of retinal laser treatment. Cardiovascular
hard end-points were defined as a history of myocardial infarction,
coronary revascularization procedure, stroke or amputation. The
clinical characteristics of the subjects with T1D in each sample are
presented in Table 2.
Genotyping of microsatellite markers
Genotyping was performed at the Finnish Genome Center. The
procedure was conducted using the MegaBACE (GE Healthcare
Life Sciences, Piscataway, NJ, USA) or the ABI genotyping
systems (Applied Biosystems, Foster City, CA, USA) and the LMS-
MD10 microsatellite marker set (Applied Biosystems) as previously
described [17]. The marker set consisted of 384 markers with a
9.5 cM average inter-marker distance and covered all autosomes
and the X chromosome. A further 13 markers were genotyped at
chromosome 3q in the Finnish sample resulting in a coverage of
2.4 cM average intermarker distance from marker D3S1558 to
D3S3668. All three sample sets were further genotyped with four
markers at 22q resulting in a coverage of 6.9 cM average inter-
marker distance from marker D22S420 to D22S1163. The
Mendelian inconsistencies of the genotypes were detected using
the PedCheck1.1 program [18].
Genotyping of the HLA loci
HLA DQA1-DQB1 haplotypes and DRB1*04 subtypes of
DQB1*0302 positive haplotypes were screened in the Finnish
families using the PCR-based lanthanide-labelled oligonucleotide
hybridization and time-resolved fluorometry detection as de-
scribed earlier [19].
Statistical analyses
Initially, two-point non-parametric affected sib-pair (ASP)
(DN+/DN+) linkage analysis was performed genome-wide. This
analysis, as well as the transmission-disequilibrium-test (TDT),
were performed using the ANALYZE program package imple-
mented in the AUTOGSCAN software tool [20]. The identity-by-
descent (IBD) of each sib-pair was estimated using the Merlin
software program [21]. Multipoint non-parametric linkage [22]
analyses were also performed using the Merlin program [21].
NPLpairs was used to analyze affected pairs (DN+/DN+). In order
to use the information from unaffected individuals as well, a NPL
quantitative trait linkage statistic (NPLqtl) was applied as described
previously [17,23]. Affected individuals (DN+) were coded as ‘‘1’’,
unaffected individuals (DN2) as ‘‘0’’ and those with missing
phenotypes as ‘‘x’’ (affection status unknown, patients with
microalbuminuria and non-diabetic individuals) in this analysis.
MERLIN program uses Z-score statistics to construct a likelihood
ratio test for linkage and define a LOD score statistic using the
procedure as previously described [24]. The Kong and Cox linear
model was applied to evaluate the evidence for linkage. This
model is designed to identify small increases in allele sharing
spread across a large number of families as is usually expected in a
complex disease. In all analyses, allele frequencies were estimated
by counting among all individuals. The AUTOSCAN 1.0.3.
software tool was used to automate the genome-wide analyses
[20].
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Finnish Danish French Total
N of genotyped individuals 351 114 91 556
Siblings 250 97 74 421
DN+ 63 61 34 158
DN2 130 35 38 203
Parents 87 17 16 120
DN+ 1- 1 2
DN2 -- 1 1
other relatives 14 - 1 15
DN+ 2- 1 3
DN2 7- - 7
N of families 94 46 35 175
2 parents genotyped 31 8 7 46
1 parent genotyped 25 1 2 28
0 parents genotyped 38 37 26 101
1 sibling with T1D 1 0 0 1
2 siblings with T1D 82 41 32 155
3–4 siblings with T1D 11 5 3 19
genotyped individuals/family, mean (range) 3.7 (2–11) 2.5 (2–5) 2.6(2–5)
genotyped siblings/family, mean (range) 2.7 (2–5) 2.1(2–3) 2.1(2–3)
genotyped siblings with T1D/family, mean (range) 2.1 (1–4) 2.1(2–3) 2.1(2–3)
Sib-pairs Finnish Danish French Total
DN+/+ 18 15 9 42
DN2/+ 32 36 16 84
DN2/2 56 3 14 73
T1D+/+ pairs 118 56 41 215
N=number; DN=diabetic nephropathy; T1D=Type 1 Diabetes.
doi:10.1371/journal.pone.0024053.t001
Table 2. Clinical characteristics of examined diabetic siblings according to renal status.
Finnish Danish French
Diabetic siblings Diabetic siblings Diabetic siblings
Characteristics
Normo-
albuminuria
Macroalbuminuria
and ESRD
Normo-
albuminuria
Macroalbuminuria
and ESRD
Normo-
albuminuria
Macroalbuminuria
and ESRD
N (M/F) 130 (70/60) 63 (38/25) 35 (20/15) 61 (34/27) 38 (20/18) 34 (18/16)
Age at examination (yrs) 40.7612.7 42.369.4 43.6610.6 43.469.1 45.9610.2 41.7615.6
Age at onset of diabetes (yrs) 16.3611.0 11.867.9 18.9610.5 14.068.1 18.868.8 14.7610.7
Duration of diabetes (yrs) 24.4611.8 30.668.5 24.7610.1 29.469.5 27.168.4 27.0613.9
Body mass index (kg/m
2)2 5 . 3 63.6 26.965.0 23.363.3 23.863.2 NA NA
HbA1c (%) 8.361.6 8.861.7 8.961.9 9.561.5 NA NA
Retinopathy (%) 16.3 90.2 27.0 66.7 22.9 77.0
CVD Hard (%) 3.8 33.9 NA NA NA NA
Systolic blood pressure (mmHg) 133619 144619 137619 152620 NA NA
Diastolic blood pressure (mmHg) 78610 82697 7 678 0 611 NA NA
N=Number; M=Male; F=Female; ESRD=End stage renal disease; NA=Not Applicable.
Data are summarized as mean 6 standard deviation.
doi:10.1371/journal.pone.0024053.t002
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We estimated the significance thresholds for ASP analysis of 400
markers using the formulae presented by Feingold et al. [25]. The
Lander and Kruglyak threshold for significant evidence of linkage
corresponding to a standard LOD score of 3.63 (p=0.000022)
[26] is decreased to a LOD score of 3.05 (p=0.00009). Similarly,
the threshold for suggestive linkage is reduced from p=0.00074
(LOD score of 2.19) to p=0.0023 (LOD score of 1.74). These
theoretically-derived thresholds are consistent with those obtained
via simulation by others [23,27,28].
Results
Genome-wide population-specific linkage analyses in
concordant sib-pairs
We first wanted to identify regions linked to DN in each
population sample separately utilizing the concordant DN+/DN+
sib-pairs. Summary of the best ASP and NPL results is presented
in Table 3. Plotted results of the genome-wide NPLpairs are shown
in Figure 1.
In the Finnish study sample no chromosomal region showed
significant evidence of linkage to DN in the ASP analysis.
Suggestive evidence of linkage was, however, found between DN
and four chromosomal regions: 6p21 (ASP LOD score 2.31),
16p12 (ASP LOD score 1.82), 17q25.3 (all-ASP LOD score 2.04),
and 22q11 (ASP LOD score 2.09) (Table 3). Nominal evidence of
linkage (only LOD Scores above 1.00 are considered) was found to
eight additional chromosomal regions (Table 3, Table S1). Two of
these regions, i.e. 3q24 and 19q13, are of interest since they have
been indicated as DN loci in previous studies [7–10].
In order to pool information from multiple markers we also
performed a multipoint, nonparametric NPLpairs analysis. The test
indicated suggestive evidence of linkage between DN and 6p21
(NPLpairs LOD score 2.10), and 16p12 (NPLpair LOD score 2.09).
In the Danish sample, no chromosomal region showed
significant or suggestive evidence of linkage to DN in the ASP
analysis. Nominal evidence of linkage was found to six
chromosomal regions (Table S1). Multipoint, nonparametric
NPLpairs analysis indicated several loci also supporting linkage to
22q11.
In the French sample, ASP analyses showed suggestive evidence
of linkage between DN and 6p23 (all-ASP LOD score 2.61) and
9p21 (all-ASP LOD score 1.94). Nominal evidence of linkage was
found to five additional chromosomal regions including 22q
(Table S1). Results of the multipoint, nonparametric NPLpairs
analysis supported evidence of linkage to most of these regions and
also indicated linkage to 7q36 and 16q12 (Table S1).
Genome-wide joint analysis of the concordant Finnish,
Danish, and French sib-pairs
Results of a joint ASP analysis of the Finnish, Danish and
French families showed suggestive evidence of linkage between
DN and 22q11 (ASP LOD score 2.78, Table 3). When multipoint
NPLpairs analysis was applied, the linkage result at 22q11
improved showing significant evidence of linkage between
D22S420 and DN (NPLpairs LOD score 3.58, Table 3). Joint
ASP analysis also indicated suggestive evidence of linkage between
DN and 6p21 (ASP LOD score 2.82). The results from the joint
analyses are presented in Figure 1, Table 3 and Table S1.
HLA-locus at 6p21 in the Finnish sample
We decided to study the 6p21 region further and genotyped the
Finnish patients for the common HLA DR-DQ haplotypes. We
also analyzed the Finnish sample set for T1D, and found
significant evidence of linkage to the HLA-region on 6p21
(NPLpairs LOD score of 5.44) providing validation that our patient
population is comprised of T1D patients [29]. TDT analysis of the
HLA locus gave an overall p-value of 9.8?10
27 for DN. However,
this was mainly driven by the major known T1D risk haplotype
DRB1*0401_DQB1*0302, p-value for this allele was 2.6?10
25 for
DN. All DN+/DN+ pairs are by definition also concordant for
T1D.
Identical-by-descent (IBD) estimation
IBD analysis estimates the probabilities that pairs of individuals
share marker alleles identical by descent. Probabilities that a given
sib-pair will share 0, 1 or 2 alleles IBD are 25%, 50% and 25%.
The estimation of the IBD was performed for the loci showing
either significant (22q11) or suggestive (6p22, 9p21, 16p12)
evidence of linkage in the ASP analysis and for the two loci
previously indicated in DN (3q21–q25 and 19q13). IBD estimation
indicated true linkage between DN and 22q11, 3q24, 9p21, 16p12
and 19q13 (Table 4).
NPLqtl analysis on concordant and discordant sib-pairs
In order to obtain additional linkage information from
unaffected individuals (DN2 i.e. normoalbuminuric T1D pa-
tients), we used a non-parametric quantitative trait linkage NPLqtl
Z-score statistic. In the Finnish sample suggestive evidence of
linkage between DN and loci on 5p15-p14 and 15q15 was
detected (Table 3). Two consecutive markers at 5p15-p14 showed
linkage (NPLqtl LOD scores 2.06 at 46 cM and 1.94 at 37 cM).
The linkage peak at 15q15 (NPLqtl LOD score 1.74 at 43 cM) was
surrounded by two markers also indicating linkage (LOD scores
1.42 and 1.56, Table S1). Nominal evidence of linkage was found
to four other chromosomal regions including 22q11 (Table S1).
In the Danish sample nominal evidence of linkage was detected
to 5q33.2 and 22q11 (Table S1).
In the French sample, suggestive evidence of linkage between
9p21 and DN (NPLqtl LOD score 2.19) was detected (Table 3).
Nominal linkage was found to two markers surrounding the 9p21
peak and to a locus on 6p23 (Table S1).
When all three sample sets were analyzed jointly nominal
evidence of linkage to five different chromosomal regions,
including 22q11, was detected (Table 3 and Table S1).
Fine-mapping the loci on 22q11 and 3q24
Since the joint analysis of the Finnish, Danish and French
families showed significant evidence of linkage to 22q11, we
genotyped four additional markers on 22q11–q12 in all three
study samples to increase the linkage information across the
implicated region. The highest linkage peak was found at 3 cM
(D22S420, NPLpairs LOD score of 2.19) even after these markers
were included in the analysis. The results are detailed in Figure 2
and Table 3.
Since the 3q21–q25 region has been suggested as a DN
susceptibility region in several previous studies [7–10], we decided
to fine-map the region in the Finnish sample by genotyping 13
additional markers (data not shown) around our linkage peak at
3q24 (150.6 cM, NPLqtl LOD score 1.36, D3S1569). When the 13
markers were included in the analysis, the highest peak was found
at 152.3 cM (NPLqtl LOD score of 1.05, D3S1593).
Discussion
The present study was conducted in three different population
samples, the Finnish, the Danish, and the French, among which
Diabetic Nephropathy Locus at 22q11
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evidence of linkage (NPLpairs LOD score 3.58) between DN and
22q11 in the joint analysis of the Finnish, Danish and French T1D
families. When analyzed separately, the samples showed either
suggestive or nominal evidence of linkage between DN and 22q11.
The IBD pattern in all three samples indicated that concordant
sib-pairs share two alleles more often than expected while
discordant pairs do not share alleles more often than expected.
For example, when viewing marker D22S420 in the Finnish
sample 45% of the DN+/DN+ pairs share two alleles while 27% of
the DN+/DN2 pairs share two alleles. This difference indicates
that our finding is most likely due to DN and not to T1D. Similar
effect was observed in the joint sample where the corresponding
values were 38% and 20%. After fine-mapping the region around
the 22q11 locus the best linkage signal was detected at 3 cM
(D22S420) and this locus does not overlap with any previously
reported DN locus detected in patients with T1D. On the other
hand, a locus approximately 20 Mb apart from our susceptibility
region has in the FIND Study recently been linked to urinary
albumin:creatinine ratio in Mexican-Americans with diabetes
[31]. This region contains the MYH9 (myosin, heavy polypeptide
9, non-muscle) and APOL1 (Apolipoprotein L1) genes associated in
African-Americans with diabetic or nondiabetic nephropathy [32–
34].
The 22q11 region contains over 60 protein coding genes. Two
of these are especially relevant candidates for DN: IL-17RA
encodes interleukin 17 receptor precursor protein, a ubiquitous
type I membrane glycoprotein that binds with low affinity to
interleukin 17A. Interleukin 17A and its receptor play a
pathogenic role in many inflammatory and autoimmune diseases
such as rheumatoid arthritis [35]. Inflammation is a major
pathogenic mechanism in DN, including such proinflammatory
molecules as cytokines IL-1, IL-6, and IL-8 [36,37]. SLC25A18
(solute carrier family 25, member 18) nuclear gene encoding
Table 3. Summary of the non-parametric linkage results for diabetic nephropathy on the regions showing significant or
suggestive evidence of linkage.
Non-parametric two-point Non-parametric multipoint
Chr cM Marker
a ASP LOD All-ASP LOD NPLpair LOD NPLqtl LOD
Finnish 5p15 36.73 D5S416 0.13 0.95 0.18 1.94
5p14 46.2 D5S419 0.07 1.20 0.20 2.06
6p21 47.9 D6S276 2.31 0.43 2.10 0.24
15q15.1 42.62 D15S994 0.08 1.28 0.42 1.74
16p12 49.5 D16S3068 1.82 0.28 2.09 0.28
17q25.3 129.62 D17S784 0.22 2.04 0.34 1.35
22q11 2.96 D22S420 2.09 0.07 1.30 0.32
Danish 22q11 2.96 D22S420 0.66 0.59 1.35 1.15
French 6p23 34.61 D6S289 1.36 2.61 1.18 1.20
9p21.2 51.5 D9S161 0.83 1.94 1.15 2.19
22q11 2.96 D22S420 0.33 0.00 0.97 0.01
Joint 6p23–p22.3 34.61 D6S289 1.79 2.41 1.95 1.49
6p22.3 42.83 D6S422 1.06 0.27 2.04 0.27
6p21 47.93 D6S276 2.82 0.37 2.35 0.04
7q21.11 162.09 D7S669 0.14 1.92 0.23 0.75
22q11 2.96 D22S420 2.78 0.31 3.58 0.86
Joint including finemapping
markers
22q11 2.96 D22S420 2.78 0.31 2.19 0.60
22q11.21 5.8 D22S427
a 0.51 0.12 1.69 0.82
22q11.21–q22 14.68 D22S539 0.47 0.82 1.43 1.49
22q11.23 18.8 D22S1174
a 1.49 1.13 1.28 1.20
22q11.23–q12.1 22.59 D22S315 0.07 0.6 0.86 1.37
22q12.1 24.38 D22S1154
a 0.15 0.64 1.09 1.33
22q12.1 30.54 D22S1163
a 0.71 0.74 0.84 0.52
Chr=chromosome; cM=centiMorgan; ASP=two-point affected sib-pair LOD score; NPL=multi-point non-parametric LOD score based on Merlin sib-pair analysis;
NPLqt l=multi-point non-parametric LOD score based on Merlin qtl-analysis;
aadditional markers genotyped on chromosome 22q.
Results on D22S420 are shown in each population and results after mapping four additional markers on chromosome 22q11–q12 in the joint sample set.
doi:10.1371/journal.pone.0024053.t003
Figure 1. Results of the genome-wide linkage analysis for diabetic nephropathy. The graphs show values for the Finnish (blue curves),
Danish (red curves), French (green curves) and the joint study samples (purple curves) in the multipoint NPLpairs analysis. For each chromosome,
genetic distance (cM) is plotted on the x-axis against the LOD score on the y-axis. Lower horizontal dotted lines represent suggestive evidence
(LOD$1.74) and upper horizontal lines show threshold for significant evidence (LOD$3.05) of linkage by Feingold et al. [25] criteria.
doi:10.1371/journal.pone.0024053.g001
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glutamate across the inner mitochondrial membrane [38]. It is
expressed in various tissues including brain, pancreas, liver and
kidney. Previous studies have revealed that polymorphisms in
other solute carriers might contribute to genetic susceptibility to
DN in type 2 diabetes in Asian populations (T2D) [39,40]. The
22q11 linkage region also contains some segments coding for
microRNAs (miRNAs, small noncoding RNA molecules) which
regulate gene expression. Recent evidence indicates that miRNAs
in general may be involved in the pathogenesis of diabetes [41].
The 22q11–q12 region also contains low-copy repeats and is
known for its susceptibility to genomic rearrangements due to non-
allelic homologous recombination. Various syndromes including
the velo-cardia-facial/diGeorge syndrome, the cat-eye syndrome,
schizophrenia, and glial tumors of the brain [42–44] have been
linked to this region. Copy number variants as such account for a
major proportion of human genetic polymorphism but their role in
genetic susceptibility to common diseases such as diabetes is still
unknown.
In addition to the 22q11 locus, our study further confirms the
previously reported susceptibility loci for DN in T1D on 3q21–q25
and 19q13. Including our report, 3q21–3q25 has now been
indicated as a susceptibility region for DN in four different
populations: the American Caucasians [7,8], Finns [9,11], Danish
(this study) and Russians [10]. Existing data implies that the 3q21–
q25 region may contain several loci involved in DN. Future studies
will define the role of these loci in DN across populations. The
locus found on 19q13 overlaps with a region recently reported in a
study on 100 American Caucasian sib-pairs discordant for DN [8].
The SNP rs306450 (at 61.2 Mb) indicating linkage in the study by
Rogus et al. is 400 kb apart from the marker D19S210 showing
linkage to DN in the Finnish sample. The area contains several
genes coding for zinc finger proteins that are relevant candidates
for further studies [45].
In addition to these three susceptibility loci, we identified in
each population other possible DN loci. In the French sample two
susceptibility regions were found on chromosome 9. The
susceptibility region on 9p21.3 has in previous studies shown to
harbor two major disease susceptibility loci: one for T2D [46,47]
and one for coronary artery disease and myocardial infarction
[48,49]. On the 9q21–q31 susceptibility region several markers
indicated linkage to DN. At least two previous studies have
indicated association between diabetic nephropathy and this
region. Common SNPs near the FRMD3 (FERM domain
containing 3) gene have been associated with DN in Northern
American populations with T1D [14]. AUH gene (AU RNA
binding protein/enoyl-Coenzyme A) on the other hand, has been
implicated in T2DM-ESRD in African Americans [50]. In the
Finnish sample susceptibility loci on 16p12 and 15q14–q22 were
identified. The 16p locus is 13 Mb apart from a locus suggested to
affect duration of diabetes to T2DM-ESRD in African patients
Table 4. Identity- by-descent (IBD) sharing and results on two-point Affected Sib Pair (ASP) linkage analysis for the most
interesting diabetic nephropathy susceptibility loci.
DN+/+ DN+/2
Chr Marker Population z0 z1 z2 z0 z1 z2 ASP LOD All-ASP LOD
22 D22S420 Finland 0.12 0.43 0.45 0.22 0.51 0.27 2.09 0.06
Denmark 0.10 0.52 0.38 0.22 0.67 0.11 0.66 0.59
France 0.04 0.70 0.25 0.16 0.58 0.26 0.33 0.00
All 0.10 0.52 0.38 0.21 0.59 0.20 2.78 0.31
22 D22S539 Finland 0.24 0.53 0.24 0.31 0.51 0.18 0.00 0.46
Denmark 0.07 0.54 0.39 0.28 0.51 0.20 0.72 0.19
France 0.04 0.43 0.53 0.11 0.48 0.41 1.59 0.15
All 0.13 0.51 0.36 0.26 0.51 0.23 0.47 0.82
3 D3S1569 Finland 0.08 0.48 0.44 0.22 0.65 0.12 0.76 1.08
6 D6S276 Finland 0.09 0.30 0.61 0.09 0.36 0.55 2.31 0.43
9 D9S161 France 0.02 0.49 0.49 0.20 0.57 0.23 0.83 1.94
16 D16S3068 Finland 0.06 0.47 0.47 0.24 0.40 0.35 1.82 0.28
19 D19S210 Finland 0.07 0.43 0.50 0.16 0.59 0.26 1.61 0.11
DN+/+=concordant for diabetic nephropathy; DN+/2=discordant for diabetic nephropathy; Chr=chromosome; z0=0 alleles; z1=1 allele; z2=2 alleles.
Figures represent probabilities of sharing either 0, 1 or 2 alleles presented as mean values.
doi:10.1371/journal.pone.0024053.t004
Figure 2. Results of multipoint linkage analysis on chromo-
some 22q. The graphs show the NPLpairs results on diabetic
nephropathy obtained in the joint sample set in the original genome-
wide screen (red curve) and after fine-mapping markers were included
in the analysis (blue curve).
doi:10.1371/journal.pone.0024053.g002
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Find Study [31] has reported a possible DN susceptibility locus in
American Indians in this region. In the Danish sample two
consecutive markers on 10p12–p13 indicated linkage to DN close
to a region reported previously in the Irish T1D sample [8,52].
The strength of our study design is the use of both concordant
and discordant sib-pairs as well as other relatives. This is evident
especially when we view the Finnish sample and the loci at 22q11,
3q24 and 5p14–p15. The locus at 22q11 was detected in the
analysis of the concordant sib-pairs. The two other loci surfaced in
the NPLqtl analysis that is able to retrieve information also from
unaffected individuals thus increasing the number of the families in
the analysis. We also looked at the IBD sharing patterns on several
loci. The results of this analysis support the loci on 22q11, 3q24,
9p21, 16p12, and 19q13 as true DN loci. Linkage to the 6p21
HLA-region, on the other hand, is probably due to T1D since
61% of the DN+/DN+ pairs and 55% of the DN+/DN2 pairs
share both alleles.
A limitation in our study is the sample size. The power to detect
susceptibility loci with moderate effects is relatively low, especially
when each sample is studied alone. However, all the samples are
part of thoroughly characterized and prospectively followed
cohorts that have generated a large amount of clinically useful
information and contributions to our understanding of the
pathogenesis of DN.
The two GWAS performed to date have detected DN
susceptibility regions on chromosomes 9q [14], 11p [14] and
10p [52] in T1D. It is not surprising that 22q11 was not detected
in these studies. While GWAS are effective in detecting common
variants with low or medium effect in a large number of unrelated
cases, linkage studies can be efficient in identifying families
enriched with rare susceptibility variants. Another advantage of
linkage analysis is that the likelihood of false positive findings due
to population stratification is reduced. Furthermore, the possibility
to test allelic transmission decreases the number of Mendelian
inconsistent genotypes.
In summary, we found significant evidence of linkage between a
novel locus on 22q11 and DN. This may indicate that the locus is
of importance in the European populations. Our results further
support the previous linkage findings between DN and chromo-
somes 3q21–q25 and 19q13 and implicate several other possible
loci in the pathogenesis of DN in T1D.
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